High impact
Pharmacy Policies Available Online
Blue Cross Blue Shield of North Dakota·Effective Sep 9, 2026
BCBSND released comprehensive pharmacy policy updates effective September 9, 2026, affecting 20+ medications across oncology, immunology, rheumatology, and other specialties. Changes include new FDA-approved indications (e.g., Datroway for triple-negative breast cancer, Fasenra for HES, Imfinzi for bladder cancer), revised prior authorization criteria, updated ICD-10 diagnosis codes, new biosimilar products, and administrative restructuring of authorization durations. Billing teams must update systems to reflect new covered diagnoses, dosing parameters, and clinical criteria before the effective date.